LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "binding interface" as a keyword



Photo from wikipedia

Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion

Sign Up to like & get
recommendations! Published in 2021 at "Biochemical and Biophysical Research Communications"

DOI: 10.1016/j.bbrc.2021.08.036

Abstract: Following the initial surges of the Alpha (B.1.1.7) and the Beta (B.1.351) variants, a more infectious Delta variant (B.1.617.2) is now surging, further deepening the health crises caused by the pandemic. The sharp rise in… read more here.

Keywords: immune evasion; variant 617; binding interface; delta variant ... See more keywords

Wavelength-Dependent Fluorescent Immunosensors via Incorporation of Polarity Indicators near the Binding Interface of Antibody Fragments.

Sign Up to like & get
recommendations! Published in 2019 at "Analytical chemistry"

DOI: 10.1021/acs.analchem.9b00445

Abstract: Herein, we describe a fluorescent immunosensor designed by incorporating an unnatural amino acid fluorophore into the binding site of an EGFR-specific antibody fragment, resulting in quantifiable EGFR-dependent changes in peak fluorescence emission wavelength. To date,… read more here.

Keywords: polarity; antibody; binding interface; wavelength dependent ... See more keywords

Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan.

Sign Up to like & get
recommendations! Published in 2025 at "ACS medicinal chemistry letters"

DOI: 10.1021/acsmedchemlett.5c00071

Abstract: Here we harnessed the unexplored binding interface between the 16-residue peptide (P) agonist and death receptor 5 (DR5). P is a solitary peptide ligand that mimics TRAIL (the natural ligand to death receptor) and is… read more here.

Keywords: binding interface; death receptor; dr5; via alanine ... See more keywords

Novel Natural Ligand Chimeric Antigen Receptors (CARs) Targeting CD70 with a Redesigned CD27 Binding Interface Provide Enhanced Potency Against Acute Myeloid Leukemia

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-204895

Abstract: Introduction: Chimeric antigen receptor (CAR) T cell therapies have brought tremendous progress in the treatment of B lymphoid and plasma cell malignancies, but development for acute myeloid leukemia (AML) has been difficult. CD70 is an… read more here.

Keywords: binding interface; car; leukemia; cd8 cd27 ... See more keywords